NCT04303429尚未招募3 期
Adjuvant Chemotherapy Versus Observation in Stage II Colon Cancer Patients With High-Risk Factors and High-Immunoscore®
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine0 个研究点目标入组 962 人开始时间: 2020年8月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 962
- 主要终点
- Disease Free Survival (DFS)
研究概览
简要总结
- Benefit of adjuvant chemotherapy after curative surgery for stage II Colon Cancer is still debated. Several high-risk features may help to stratify stage II cancer patients into groups that will truly benefit from adjuvant chemotherapy. However, those factors are rather subjective, and no specific trial has been designed to answer the high-risk stage II colon cancer question directly.
- Immunoscore® Colon, an in vitro diagnostic test, which quantifies the density of CD3+ and CD8+ T lymphocyte populations in the center the tumor (CT) and its invasive margin (IM) using immunohistochemistry and automated image analysis. Immunoscore® has been extensively validated as a prognostic biomarker in early stage CC patients. This unique diagnostic assay measuring host immune response at the tumor site may inform the decision to administer adjuvant chemotherapy in resected Stage II and III CC patients.
- This randomized trial is studying how observation compares to adjuvant chemotherapy (investigator's choice) in stage II colon cancer patients with high-risk features and High-Immunoscore®. The trial would represent a unique opportunity to classify stage II CC patients based on their tumor microenvironment with the aim to provide efficient patient stratification to improve clinical care.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-75 years old
- •Pathologically confirmed adenocarcinoma of the colon
- •Complete resection of the primary tumor without gross or microscopic evidence of residual disease
- •Histologically proven stage II: T3-T4 N0
- •At least one of the following factors:T4 staging,Number of examined lymph nodes < 12,poor differentiation (except MSI-H),LVI or PNI,tumor perforation or occlusion
- •Treatment within 7 weeks following surgery
- •ECOG PS 0-1
- •No prior chemo, immuno or radiotherapy
- •Patients must read, agree to, and sign a statement of Informed Consent prior to participation in this study.
- •Exclusion criteria
- •Have a birth plan during the clinical trial;
- •Severe cardiovascular diseases such as cerebrovascular accidents occurring within 6 months, myocardial infarction, hypertension that cannot be controlled after drug intervention, unstable angina pectoris, heart failure (NYHA 2-4), and arrhythmia requiring drugs Intervention;
- •Dementia, mental state changes or any mental illness that may interfere with understanding or making informed consent or completing a questionnaire;
- •Subjects with ≥1 peripheral neuropathy according to CTCAE V version 4.03;
- •Allergy or hypersensitivity history of the drug or drug ingredient used in this test;
- •Excluding other malignant tumors, cured basal cell carcinoma of the skin or squamous cell carcinoma of the skin or any other part of the carcinoma in situ;
- •Have received any other test drug treatment or participated in another interventional clinical trial within 30 days of the screening period;
- •The investigator believes that it is not suitable for inclusion.
排除标准
- 未提供
研究组 & 干预措施
adjuvant chemotherapy group
Experimental
Patients enrolled in the chemotherapy group will receive postoperative chemotherapy (investigator's choice) for 3 months or 6 months.
干预措施: FOLFOX/XELOX/Capecitabine (Drug)
结局指标
主要结局
Disease Free Survival (DFS)
时间窗: 3 years
To evaluate the noninferiority of observation as compared to standard of care adjuvant chemotherapy (investigator's choice) in patients with high-risk stage II CC and High-Immunoscore® in terms of disease free survival (DFS).
次要结局
- Overall Survival (OS)(From date of enrollment until the date of death,assessed 1year,3years and 5years after therapy)
- Time to Recurrence (TTR)(From date of enrollment until the date of recurrence,assessed 1year,3years and 5years after therapy)
研究者
Qi Li
Executive director of cancer center
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
相似试验
尚未招募
不适用
A 6 microRNA Tool for Stratifying Stage II Colon Cancer of Receiving Adjuvant ChemotherapyColonic NeoplasmsEffects of ChemotherapyNCT02466113First Affiliated Hospital, Sun Yat-Sen University430
招募中
不适用
Adjuvant Chemotherapy in Clinical Local Advanced CRC Following Preoperational Therapies and pT0-3N0M0 DiagnosisAdjuvant ChemotherapyColorectal CancerNCT03748485Sixth Affiliated Hospital, Sun Yat-sen University650
招募中
2 期
Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%Chemotherapy, AdjuvantLung Adenocarcinoma, Stage ITreatmentHistological Type of NeoplasmNCT03351842Shanghai Pulmonary Hospital, Shanghai, China460
已完成
2 期
Postoperative Chemotherapy and Chemo-radiotherapy for Resected Gastric CancerGastric CancerNCT00718913Hellenic Oncology Research Group40
尚未招募
不适用
Outcome of Neoadjuvant Chemotherapy for Obstructive Colon CancerColon Cancer, ObstructionNCT04889820The Catholic University of Korea204